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Abstract: Latent EBV infection is associated with several malignancies, including EBV post
transplant  lymphoproliferative
nasopharyngeal carcinoma and Burkitt lymphoma. The range of expression of latent EBV 
antigens  varies  in  these  tumors,  which  influences  how  susceptible  the  tumors  are  to 
immunotherapeutic approaches. Tumo
the  widest  array  of  EBV  antigens  making  them  the  most  susceptible  to  immunotherapy. 
Treatment strategies for EBV-
adoptive immunotherapy with EBV
monoclonal antibodies. We review the current immunotherapies and future studies aimed at 
targeting EBV antigen expression in these tumors.
Introduction:  By  adulthood,  over  95%  of 
individuals  have  been  infected  with  Epstein
virus (EBV), which can cause either a mild, self
limiting  infection  in  childhood  or  infectious 
mononucleosis in adolescents. EBV enters the body 
via the oropharynx and infects resting B cells and/or 
epithelial  cells
1.  Because these  B  cells are  highly 
immunogenic,  they induce an expansion of virus
specific  and  nonspecific  T  cells  that  results  in 
regression  of  infected  B  cells;  however,  a  small 
number of B cells express only a limited array of 
less immunogenic EBV antigens, such as EBNA
and  in  some  cases  express  no  EBV  ant
allowing these EBV-infected B cells to evade the 
immune  response  so  that  the  virus  can  persist  in 
latency for the life of the individual
; Open Journal System 
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Latent EBV infection is associated with several malignancies, including EBV post
transplant  lymphoproliferative disorders  (LPD),  Hodgkin  and  non-Hodgkin  lymphomas, 
nasopharyngeal carcinoma and Burkitt lymphoma. The range of expression of latent EBV 
antigens  varies  in  these  tumors,  which  influences  how  susceptible  the  tumors  are  to 
immunotherapeutic approaches. Tumors expressing type III latency, such as in LPD, express 
the  widest  array  of  EBV  antigens  making  them  the  most  susceptible  to  immunotherapy. 
-related tumors include restoring normal cellular immunity by 
h EBV-specific T cells and targeting the malignant B cells with 
monoclonal antibodies. We review the current immunotherapies and future studies aimed at 
targeting EBV antigen expression in these tumors.
By  adulthood,  over  95%  of 
individuals  have  been  infected  with  Epstein-Barr 
virus (EBV), which can cause either a mild, self-
limiting  infection  in  childhood  or  infectious 
mononucleosis in adolescents. EBV enters the body 
ng B cells and/or 
.  Because these  B  cells are  highly 
uce an expansion of virus-
specific  and  nonspecific  T  cells  that  results  in 
regression  of  infected  B  cells;  however,  a  small 
number of B cells express only a limited array of 
less immunogenic EBV antigens, such as EBNA-1 
and  in  some  cases  express  no  EBV  antigens, 
infected B cells to evade the 
immune  response  so  that  the  virus  can  persist  in 
latency for the life of the individual
2. Reactivations 
can occur, but are usually readily controlled by the 
EBV-specific immune response.
EBV-Related  Malignancies:
associated with a heterogeneou
malignancies, including Hodgkin disease (HD), NK 
and  T  cell  lymphomas,  Burkitt  lymphoma  and 
lymphoproliferative disorders (LPDs)
are  EBER  positive,  the  EBV  latent  protein 
expression varies, and three distinct types of
latency have been characterized with type I being 
least  immunogenic  and  type  III  the  most 
immunogenic
3 (Figure 1). Type III latency tumors 
include LPDs which have the same phenotype as 
vitro generated  lymphoblastoid  cell  lines  (LCLs) 
and  occur  in  immunocompromised  hosts.  These 
tumors express a full array of latent EBV antigens 
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Latent EBV infection is associated with several malignancies, including EBV post-
Hodgkin  lymphomas, 
nasopharyngeal carcinoma and Burkitt lymphoma. The range of expression of latent EBV 
antigens  varies  in  these  tumors,  which  influences  how  susceptible  the  tumors  are  to 
rs expressing type III latency, such as in LPD, express 
the  widest  array  of  EBV  antigens  making  them  the  most  susceptible  to  immunotherapy. 
related tumors include restoring normal cellular immunity by 
specific T cells and targeting the malignant B cells with 
monoclonal antibodies. We review the current immunotherapies and future studies aimed at 
can occur, but are usually readily controlled by the 
specific immune response.
Related  Malignancies: Latent  EBV  is 
associated with a heterogeneous group of lymphoid 
malignancies, including Hodgkin disease (HD), NK 
and  T  cell  lymphomas,  Burkitt  lymphoma  and 
lymphoproliferative disorders (LPDs)
3-5. While all 
are  EBER  positive,  the  EBV  latent  protein 
expression varies, and three distinct types of EBV 
latency have been characterized with type I being 
least  immunogenic  and  type  III  the  most 
. Type III latency tumors 
include LPDs which have the same phenotype as in 
generated  lymphoblastoid  cell  lines  (LCLs) 
and  occur  in  immunocompromised  hosts.  These 
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Figure 1.  Types of EBV Latency
(EBNA-1, 2A, 2B, 3A, 3B, 3C, LP, and LMP1 and 
2)  and  major  histocompatibility  complex  (MHC) 
class I/II and costimulatory molecules, making them 
highly  immunogenic  and  susceptible  to 
immunotherapy.  Type  II  latency  (HD  and  NK/T 
lymphomas) express a more restricted EBV antigen 
expression pattern including the subdominant EBV 
antigens, LMP1 and LMP2, but also express MHC 
Class  I/II  and  costimulatory  molecules.  These 
tumors  generally  arise  in  the  immunocompetent 
host  and  employ  multiple  immune  evasion 
strategies including  restricted  antigen  expression. 
Type I latency (Burkitt lymphoma) is defined by the 
presence  of  EBNA-1  without  expression  of  other 
latent  antigens;  thus,  these  tumors  are  the  least 
immunogenic and therefore the least susceptible to 
T-cell immunotherapy. 
Immunotherapy For Type Iii Latency Tumors: 
The  balance  between  EBV-derived  B-cell 
proliferation  and  cellular  immunity  that  exists  in 
normal  hosts  may  be  altered  in 
immunocompromised hosts so that EBV-LPD can 
occur. The onset of LPD is often preceded by viral 
reactivation  and  increased  numbers  of  latently 
infected B cells in peripheral blood
6, as detected by 
elevated levels of EBV DNA in peripheral blood or 
plasma by polymerase chain reaction
7-9. Monitoring 
of  viral  loads  is  therefore  a  sensitive  means  of 
monitoring patients at risk of developing LPD but 
the  specificity  varies  with  different  clinical 
scenarios and many immunodeficient patients will 
have an increase in circulating EBV-infected B cells 
without developing LPD
10,11.
Post-transplant  EBV-associated  Lympho-
proliferative  Disorder:  Post  transplant  EBV-LPD 
can occur following either hematopoietic stem cell 
transplant (HSCT) or solid organ transplant (SOT) 
due to the immune suppression required to prevent 
graft-versus-host disease (GvHD) or rejection and 
the  risk  is  related  to  the  degree  of  immune 
supression
12. The development of LPD is strongly 
associated with a defective  T-cell immune response 
to  EBV  but  other  immunologic  factors  such  as 
cytokine  polymorphisms  may  also  influence  the 
risk
13. 
In HSCT the highest incidence of EBV-LPD is 
seen  in  the  first  3  to  6  months  prior  to  T-cell 
immune  recovery.  Whereas  EBV-specific  cellular 
immunity  is  rapidly  re-established  in 
unmanipulated,  matched  sibling  graft  recipients,  
immune  reconstitution  is  significantly  delayed  in 
patients receiving T-cell depleted grafts, unrelated 
or  mismatched  related  donor  grafts  or  recipients 
who receive T-cell depleting antibodies in vivo
14,15. 
Hence, the risk of developing EBV-LPD varies with Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
different stem cell sources and manipulation with 
those receiving stem cells from unrelated or HLA-
mismatched  unrelated  donors  having  the  greatest 
risk, due to either T-cell depletion of the graft or 
administration  of  T-cell  depleting  antibodies  to 
prevent GvHD. However, depletion methods using 
Campath-1H  (anti-CD52)  remove  both  T  and  B 
cells and is associated with lower rates of EBV
16,17. 
EBV-LPD post HSCT is typically of donor origin, 
while  EBV-LPD  post  SOT  generally  arises  from 
recipient  hematopoietic  cells  although  can  arise 
from transferred B cells in the grafted organ. The 
overall incidence of EBV-PTLD after SOT is less 
than 1% but can be as high as 31%, depending on 
the  organ  transplanted  and  the  level  of  immune 
suppression
18.
CD20  Monoclonal  Antibody  Therapy: 
Immunotherapies to prevent and treat EBV revolve 
around two crucial concepts: 1) removal of EBV-
infected  B  cells  or  2)  expansion  of  EBV-specific 
cell-mediated  immunity.  The  first  anti-B-cell 
antibodies used to target EBV-infected B cells were 
monoclonal antibodies against CD21, the receptor 
used by EBV to enter B cells, and CD24, an antigen 
expressed  by  B-cells  and  granulocytes,  and  some 
success  was  reported  – 57%  complete  remission, 
with  35%  long-term  survival  (follow-up,  35-72 
months).
19,20 However,  the  effects  of  subsequent 
therapy  were  short  lived,  with  the  rapid  re-
emergence  of  B  cells  (and  EBV-LPD  in  many 
cases) after treatment cessation. 
Over  the  past  9  years  the  CD20  humanized 
antibody (rituximab) has been increasingly used in 
the  EBV-LPD  setting
21.  Since  CD20  is  a  cell 
surface  antigen present  on  all  circulating  B  cells, 
this  long-acting  antibody  may  result  in  B  cell 
depletion that persists for over six  months. Many 
centers use this antibody as prevention or treatment 
of  EBV-LPD  post  HSCT  with  response  rates 
varying  between  55%  and  100%
15,22-24.  However, 
relapse can still occur after B cell recovery since 
rituximab  does  not  restore  cellular  immunity  to 
EBV
9. 
Donor Lymphocyte Infusions: The simplest T-cell 
immunotherapeutic  approach  to  treat  viral 
infections post HSCT is the use of unmanipulated 
donor  lymphocyte  infusions  (DLI),  which  can  be 
easily obtained via a simple blood draw. Since most 
EBV-seropositive individuals have a high frequency 
of  EBV-specific  precursors,  the  transfer  of 
unmanipulated  DLI  should  restore  the  immune 
response to EBV. While DLI infusions post HSCT 
can effectively eradicate EBV-LPD as early as 2 to 
4 weeks post infusion
25, the risk of graft-versus-host 
disease  (GvHD)  due  to  alloreactivity  makes  DLI 
treatment for EBV-LPD a less attractive option than 
more specific EBV therapies.  
Donor-derived  EBV-CTL:To  avoid  the  risk  of 
alloreactivity  observed  with  DLI,  donor-derived 
EBV-specific  CTL  can  be  generated  in  the 
laboratory  for  adoptive  immunotherapy.  Since 
EBV-CTL  circulate  in  normal  donors,  ex  vivo
expansion of the EBV-CTL is feasible for patients 
post HSCT. Polyclonal EBV-CTL lines for clinical 
use can be selectively generated in the laboratory by 
stimulating  donor  peripheral  blood  mononuclear 
cells  (PBMC)  with  donor-derived,  EBV-
transformed B lymphoblastoid cells lines, which act 
as  highly  effective  antigen  presenting  cells
26-29. 
These  EBV-CTLs  contain  both  CD4- and  CD8-
positive T cells that recognize multiple latent and 
lytic viral antigens. EBV-CTL infusions to prevent 
or  eradicate  EBV  infection  have  been  very 
efficacious  in  the  post  HSCT  setting.  We  have 
recently reviewed the long term follow up on 114 
patients  who  had  received  infusions  of  EBV-
specific  cytotoxic T  lymphocytes  (CTLs) at  three 
different  centers  to  prevent  or  treat  EBV-positive 
lymphoproliferative  disease  (LPD)  arising  after 
hematopoietic stem cell transplantation
30  . Of the 
101 patients who received CTL prophylaxis, none 
developed  EBV-positive  LPD
30.  13  patients  were 
treated  with  CTLs  for  biopsy-proven  or  probable 
LPD  and  11  achieved  sustained  complete 
remissions
30.  Several  other  groups  have  also 
confirmed  the  activity  of  EBV-CTLs  in  treating 
LPD  following  transplant  including  LPDs  
persisting after treatment with Rituximab
31,32.
Autologous EBV-CTLs: Whereas donor-derived 
EBV-CTL has been shown to be efficacious in the 
post  HSCT  setting,  SOT  recipients  who  develop 
EBV-LPD have different challenges, such as lack of 
donor  availability  and  continued  immune 
suppression. To overcome these challenges, several 
groups  have  used  autologous  EBV-CTLs  in  SOT 
recipients with EBV reactivation. While the in vivo
persistence of CTLs was less than seen in donor-
derived EBV-CTLs, infusions of autologous CTLs 
have been shown to be safe and no organ rejection 
occurred  in  patients  receiving  the  CTLs
33-36. 
Clinical responses have been seen but the response 
rate is  lower  than  in  PTLD  after  HSCT,  likely 
reflecting  decreased  activity  of  CTLs  in  the 
presence of continuing immunosupression
35,36.   
Third-party EBV-CTLs: The primary downside 
to EBV-CTL generation for a specific patient is that 
it  is  expensive  and  time-consuming,  taking  up  to 
three  to  four  months  to  generate  a  suitable  CTL Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
line.  Therefore,  investigators  have  now  generated 
banks of allogeneic virus-specific CTL lines from 
normal donors, so that most closely matched CTLs 
are available for patients in need of virus-specific 
immune reconstitution
37. One concern with this “off 
the  shelf”  approach  is  that  the  recipient  may 
generate an immune response to a non-shared HLA 
antigen. In a Phase II study evaluating this approach 
these third-party CTLs were used to treat EBV-LPD 
after HSCT or SOT with encouraging results: 64% 
response  at  5  weeks  and  52%  at  6  months,  with 
better responses noted in patients most closely HLA 
matched  to  the  CTLs
37,38.  However  for  certain 
tumor  types  complete  responses  occurred  in  the 
absence  of  detectable  specific  CTL/tumor 
recognition  perhaps  because  the  population  could 
not be detected or possibly because CTLs may have 
stimulated  nonspecific  inflammatory  responses  in 
vivo
38.  This  strategy  continues  to  be evaluated in 
clinical trials. 
Rapid  Selection  of  EBV  CTLs:  There  are  two 
alternative strategies being evaluated in early phase 
trials  that  can  be  used  to  rapidly  reconstitute  an 
EBV-specific  immune  response  in  the  allogeneic 
HSCT setting. The first is to capture donor cells that 
secrete γ-IFN in response to antigenic stimulation. 
This approach can be used regardless of HLA type 
and  captures  both  CD4  and  CD8  T  cells,  but 
requires  the  donor  to  be  available  for  pheresis. 
Another  rapid  selection  strategy  is  to  use 
magnetically-labeled  peptide tetramers  to  select T 
cells  specific  for  an  EBV  epitope.  This  approach 
has  shown  promise  when  used  to  reconstitute 
immunity  to  CMV
39 but  has  the  disadvantage  of  
requiring   knowledge of peptide epitopes suitable 
for each patient’s HLA type.
Immunotherapy  For  Type  Ii  Latency  Tumors: 
Type  II  latency  EBV-associated  lymphomas 
occurring in individuals who do not have a known 
immunodeficiency include NK and T malignancies 
with cytotoxic phenotypes, and sporadic cases of B-
NHL.
5 Hodgkin’  disease is  also  associated  with 
expression  of  EBV-derived  antigens  in  malignant 
Reed-Sternberg (RS) cells in up to 50% of cases
4,40. 
While HD can be very curable  (with disease-free 
survival  approaching  80-90%,
41 survival  is  very 
poor  for  those  who  fail  salvage  chemotherapy  or 
relapse  multiple  times.  Thus,  it  is  desirable  to 
develop  novel  therapies  to  increase  survival  in 
patients  with  relapsed/refractory  disease.  EBV+ve 
NK and T malignancies respond poorly to standard 
chemotherapy  and  radiotherapy  justifying 
exploration of strategies targeting EBV.
Antibody  Therapies  for  Type  II  Latency 
Lymphomas
CD25 and CD30 Antibodies: Monoclonal antibody 
therapy  targeting  the  cell  surface  antigens,  CD25 
and CD30, present primarily on malignant RS cells 
could be a very attractive immunotherapy approach 
for  HD.  These  monoclonal  antibodies  can  be 
chemically  linked  to  an  active  toxin  such  as 
Pseudomonas endotoxin A or deglycosylated ricin 
A
42,43.  Initial studies were limited by the  immune 
response  against  murine  antibodies  and  the  toxin 
component but studies with humanized antibodies 
are now underway
44. 
T-Cell  Therapies  for  Type  II  Latency 
Lymphomas
Unmanipulated Allogeneic T Cells: As with type 
III  latency  EBV-LPD,  DLI  can  be  used  for 
treatment  of  patients  with  type  II  latency  HD  or 
NHL  following  allogeneic HSCT
45-47.  One  group 
administered  DLI  to  16  patients  with  residual 
disease or disease progression following transplant, 
with  nine  disease  responses  (including  eight 
complete responses). However, high rates of GvHD 
were  noted  in  the  responders  (six  severe,  acute 
GvHD and five chronic GvHD)
48. Another group 
reported a 44% response rate in nine patients with 
advanced HD who received  DLI for  persistent or 
progressive  disease  and  all  but  one  developed 
GvHD following DLI
49. Thus, further evaluations of 
DLI approaches in these patients with difficult to 
treat disease  is  warranted  however,  developing 
strategies  to  maximize  efficacy  while  minimizing 
toxicity is crucial.
EBV-specific  CTLs:  In  type  II  latency  EBV-HD 
and  NHL,  viral  gene  expression  is  limited  to  
immunosubdominant proteins, including LMP1 and 
LMP2,  which  are  weak  targets  for  CTL  activity, 
thereby  allowing  malignant  cells  to  evade  the 
immune  system.  Immunotherapy  targeting  these 
subdominant  EBV  antigens  has  been  undertaken 
with  some  success,  in  both  the  autologous  and 
allogeneic setting. 
Our  group  initially  evaluated  the  use  of 
autologous  polyclonal  EBV-CTLs  in  14  patients 
with relapsed EBV-HD, retrovirally marking CTL 
in seven patients. Five patients achieved complete 
remissions (two with detectable disease at time of 
CTL infusion), one achieved a partial response and 
five  had stable disease
50. Tetramer and functional 
analyses revealed that T cells reactive with LMP2 
were present in the infused lines, expanded in vivo
and could track to the sites of disease. The gene-Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
marking studies proved that the infused cells could 
further  expand  by  several  logarithms  with 
persistence up to 12 months
50. 
Since  these  studies  used  EBV-CTL  which 
contained only low frequencies of T-cells specific 
for  the  tumor  associated  antigen  LMP2,  we  then 
focused efforts on using genetically modified tumor 
antigen presenting cells that overexpress LMP2 as a 
strategy to increase the frequency of LMP2-specific 
T-cells in the product administered to patients. To 
accomplish this, we used dendritic cells that were 
engineered  to  express LMP2 using  an  adenovirus 
vector  (Ad5f35LMP2A)  for  the  primary 
stimulation, and then used LCLs modified with the 
same  Ad5f35LMP2A  vector  for  subsequent 
stimulations.  Clinically,  these  LMP2-spcific  CTL 
have been  used in  a  dose-escalation  study for  16 
patients  with  high-risk  EBV-HD  and  NHL
51.  Ten 
patients  received  CTLs  as  adjuvant  therapy  with 
nine remaining in complete remission for up to four 
years. Five of six with active, relapsed disease at 
time  of  infusion  showed  disease  response  (four 
complete) sustained for more than nine months. No 
toxicities have been observed after CTL infusion.
51
To  broaden  this  approach,  we  are  now  extending 
this strategy by using autologous T cells enriched 
for  both  LMP2  and  LMP2,  in  a  clinical  trial  is 
currently underway. 
Because  it  is  difficult  to  generate  autologous 
CTL  in  sufficient  quantity  for  heavily pre-treated 
patients,  partially  HLA-matched  allogeneic  CTL 
have been generated for a phase I study in patients 
with relapsed EBV-HD
52. Five of six patients had a 
reduction in measurable disease up to 22 months. 
However, this approach was limited by the short-
term  persistence  of  the  allogeneic  T  cells  since 
donor-derived T cells could not be detected in vivo.
Artificial  T-cell  Receptors:  Subpopulations  of 
EBV-HD tumor cells may lack or lose expression of 
the weakly immunogenic antigens, such as LMP1 
and  LMP2,  thus  allowing  tumor  escape  and 
treatment  failure  with  CTLs.  The  genetic 
modification  of  human  T  cells  to  express  tumor 
antigen-specific immune receptors offers a potential 
means of targeting other tumor associated antigens 
in  addition  to  EBV.  One  approach  is  to  use 
engineered T cell αβ-receptors which can be cloned 
from autologous CTL cultures or generated in HLA 
A2 transgenic mice but this is limited by HLA-type 
and  generally  confined  to  HLA-A2  donors.  In 
addition  inadvertent  pairing  between  the  native 
TCR  and  the  transduced  αβ  chains  may  limit 
antitumor effects and cause off target side effects. A 
second approach is to incorporate chimeric antigen 
receptors  (CAR)  made  of  the  antigen  combining 
domains of antibody heavy and light chains, usually 
coupled to the intracellular components of the T cell 
receptor  zeta  chain  to  permit  signal  transduction 
after T-cell receptor engagement. 
Most  CAR-modified  T  cells  have  limited 
expansion, persistence and activity in vivo because 
they are inadequately co-stimulated. For CARs, it 
may be possible to overcome this limitation by the 
further incorporation of the endodomains of T cell 
co-stimulatory molecules such as CD28, OX40L or 
4-1-BB. Alternatively, EBV specific CTL may be 
used  as  a  CAR  platform,  since  these  cells  retain 
long-term functionality in vivo  and should receive 
all  appropriate  co-stimulation  through their native 
receptors  when  they  encounter  viral  antigens  on 
normal  antigen  presenting  cells,  improving 
expansion  and  persistence  and  permitting 
subsequent  killing  of  tumor  cells  through  their 
chimeric  receptor  directed  to  a  tumor  associated 
antigen. A recent study confirmed that EBV CTLs 
may survive longer than T cells when grafted with a 
CAR  perhaps  due  to  the  additional  costimulation 
received through their native receptor
53. 
One trial with T  cells transduced with a CAR 
specific  for  CD20  has  been  reported  and  several 
trials with CARs targeting CD19 are underway
54,55. 
In  Hodgkin’s  Disease  CD30,  which  is  highly 
expressed on malignant RS cells is a target
56 and in 
preclinical studies  CD30 CAR+ EBV-CTLs retain 
their  ability  to  kill  EBV-positive  lymphoma  cells 
and have the ability to recognize and kill CD30+
HD  tumor  cells  in  vitro and  in  vivo in  a  severe 
combined immunodeficiency murine model. 
Immunotherapy For Burkitt Lymphoma – Type 
I Latency Tumors: While many Burkitt lymphoma 
tumors  are  EBV  positive,  these  are  amongst  the 
least  immunogenic  of  the  EBV-related  tumors  as 
they express a type I latency pattern (EBNA1 is on 
the only latent protein of the virus present and EBV 
gene expression is otherwise limited to the EBERs). 
EBNA1  is  a  challenging  target  for  CTL  as  it 
possesses  the  unique  glycine-alanine  repeat  (Gar) 
sequences that inhibit the endogenous presentation 
of  CD8+  T-cell  epitopes  through  the  class  I 
pathway  by  blocking  proteasome-dependent 
degradation  of  EBNA1.  However,  since  EBNA1 
specific CD4+ T  cells can be detected in  healthy 
donors
57,  this  antigen  is  a  potential 
immunotherapeutic  target.  Several  MHC  class  II 
restricted  peptides  from  EBNA1  have  been 
identified that recognized by CD4+ T cells and the 
potential  use  of  these  cells  for  adoptive Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
immunotherapy is being explored
58-60. Additionally, 
most Burkitt lymphoma tumor cells express CD20 
on their surface, making them targets for rituximab 
therapy  (monoclonal  antibody  directed  against 
CD20).
Conclusions:  Adoptive  immuno-therapy,  ranging 
from simple B-cell antibodies to complex and time-
consuming  CTL  therapies,  offers  a  potentially 
curative  approach  to  many  patients  with  EBV-
related  malignancies.  Given  that  these  treatments 
are  usually  reserved  for  relapsed  or  refractory 
patients,  responses  vary  ranging  from  good 
complete  responses  to  stable  active  disease.  As 
researchers optimize the generation of these cells ex 
vivo allowing for enhanced in vivo persistence and 
expansion,  we  will  hopefully  begin  to  see  more 
durable  responses  in  this  heavily  pretreated 
population.
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